{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T17:16:26Z","timestamp":1792343786607,"version":"4.4.0"},"reference-count":45,"publisher":"Wiley","issue":"19","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,10]]},"abstract":"ABSTRACT<\/jats:title>\n \n Introduction<\/jats:title>\n Enfortumab vedotin\u2010ejfv (EV), an antibody\u2013drug conjugate approved for advanced urothelial carcinoma (aUC), has limited real\u2010world safety data and no validated predictive biomarkers. Retrospective studies suggest higher objective response rates (ORR) among patients developing EV\u2010related dermatologic toxicities, but survival implications remain unclear. This analysis assessed the safety of EV monotherapy and the impact of dermatologic and neurologic toxicities on efficacy outcomes in a multi\u2010institutional cohort.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods<\/jats:title>\n UNITE is a multicenter, retrospective study across 16 US sites of patients with aUC treated with targeted agents, including EV. Primary endpoints were the incidence of EV treatment\u2010related adverse events (TRAEs, any grade) and TRAE\u2010related treatment modifications. Secondary endpoints included a comparison of ORR, progression\u2010free survival (PFS), and overall survival (OS) between patients with and without dermatologic toxicities and neuropathy. To reduce immortal time bias, Cox regression models incorporated TRAEs as time\u2010dependent covariates to adjust for EV treatment duration as well as Eastern Cooperative Oncology Group performance status (ECOG PS), hemoglobin, and liver metastases.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Between 2018 and 2023, 485 patients with aUC received >\u20091 dose of EV monotherapy. Most (67%) received >\u20092 prior therapy lines. Any grade TRAEs occurred in 77%, most frequently neuropathy (36%) and dermatologic toxicities (27%); 57% required treatment modification and 21% discontinued EV, primarily due to neuropathy (9%) and fatigue (3%). Patients with dermatologic toxicities and neuropathy had higher ORR (56% vs. 42%;\n p<\/jats:italic>\n \u2009=\u20090.007 and 64% vs. 35%;\n p<\/jats:italic>\n \u2009<\u20090.0001, respectively). Neuropathy was independently associated with improved OS (HR 0.66; 95% CI 0.50\u20130.87;\n p<\/jats:italic>\n \u2009=\u20090.002); dermatologic TRAEs were not associated with PFS or OS benefit.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n EV safety outside clinical trials was consistent with prior reports, with no new signals. Treatment modifications were most often due to neuropathy, dermatologic toxicities, and fatigue. Both dermatologic toxicities and neuropathy correlated with higher ORR, but only neuropathy was independently associated with improved OS.<\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/cam4.71284","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:15:53Z","timestamp":1759320953000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Treatment\u2010Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the\n UNITE<\/scp>\n Study"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5181-490X","authenticated-orcid":false,"given":"Amanda","family":"Nizam","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology Cleveland Clinic Taussig Cancer Institute Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1898-5501","authenticated-orcid":false,"given":"Charles B.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology University of Michigan Rogel Comprehensive Cancer Center Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinju","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biostatistics University of Michigan Medical School Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1402-4498","authenticated-orcid":false,"given":"Emily C.","family":"Zabor","sequence":"additional","affiliation":[{"name":"Department of Quantitative Health Sciences Cleveland Clinic Lerner Research Institute Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6505-8308","authenticated-orcid":false,"given":"Pavlos","family":"Msaouel","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2459-1875","authenticated-orcid":false,"given":"Cindy Y.","family":"Jiang","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9658-2206","authenticated-orcid":false,"given":"Omar","family":"Alhalabi","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4125-603X","authenticated-orcid":false,"given":"Eugene","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Michigan Medical School Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1480-9423","authenticated-orcid":false,"given":"Matthew P.","family":"Davidsohn","sequence":"additional","affiliation":[{"name":"Genitourinary Oncology Program Dana\u2010Farber Cancer Institute\u2010IMIM Research Lab Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1085-7817","authenticated-orcid":false,"given":"Ilana B.","family":"Epstein","sequence":"additional","affiliation":[{"name":"Genitourinary Oncology Program Dana\u2010Farber Cancer Institute\u2010IMIM Research Lab Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1214-7507","authenticated-orcid":false,"given":"Dimitra Rafailia","family":"Bakaloudi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine University of Washington Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6619-2573","authenticated-orcid":false,"given":"Rafee","family":"Talukder","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology Baylor College of Medicine Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5954-3278","authenticated-orcid":false,"given":"Tanya","family":"Jindal","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4559-4159","authenticated-orcid":false,"given":"Amy K.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Wisconsin Carbone Cancer Center Madison Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9811-9004","authenticated-orcid":false,"given":"Michael J.","family":"Glover","sequence":"additional","affiliation":[{"name":"Division of Oncology Stanford University Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4655-4426","authenticated-orcid":false,"given":"Ali Raza","family":"Khaki","sequence":"additional","affiliation":[{"name":"Division of Oncology Stanford University Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Lemke","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Froedtert and the Medical College of Wisconsin Milwaukee Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Mabey","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Oncology University of North Carolina School of Medicine Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9258-8299","authenticated-orcid":false,"given":"Bashar","family":"Abuqayas","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Iowa Holden Comprehensive Cancer Center Iowa City Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0461-6174","authenticated-orcid":false,"given":"Albert","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Medicine Tulane University School of Medicine New Orleans Louisiana USA"},{"name":"Department of Medicine Case Western Reserve University\/University Hospitals Seidman Cancer Center Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6225-7555","authenticated-orcid":false,"given":"Jason R.","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Medicine Case Western Reserve University\/University Hospitals Seidman Cancer Center Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean T.","family":"Evans","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute of Emory University Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron","family":"Pywell","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Alabama at Birmingham O'neal Comprehensive Cancer Center Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8678-3880","authenticated-orcid":false,"given":"Arnab","family":"Basu","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Alabama at Birmingham O'neal Comprehensive Cancer Center Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4003-1103","authenticated-orcid":false,"given":"Mehmet A.","family":"Bilen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute of Emory University Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8890-2951","authenticated-orcid":false,"given":"Pedro C.","family":"Barata","sequence":"additional","affiliation":[{"name":"Department of Medicine Tulane University School of Medicine New Orleans Louisiana USA"},{"name":"Department of Medicine Case Western Reserve University\/University Hospitals Seidman Cancer Center Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9480-2626","authenticated-orcid":false,"given":"Yousef","family":"Zakharia","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Iowa Holden Comprehensive Cancer Center Iowa City Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8965-8129","authenticated-orcid":false,"given":"Matthew I.","family":"Milowsky","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Oncology University of North Carolina School of Medicine Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6999-1901","authenticated-orcid":false,"given":"Deepak","family":"Kilari","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Froedtert and the Medical College of Wisconsin Milwaukee Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-2410","authenticated-orcid":false,"given":"Christopher J.","family":"Hoimes","sequence":"additional","affiliation":[{"name":"Department of Medicine Duke Cancer Institute Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9479-2333","authenticated-orcid":false,"given":"Sumit A.","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Oncology Stanford University Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8506-8703","authenticated-orcid":false,"given":"Hamid","family":"Emamekhoo","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Wisconsin Carbone Cancer Center Madison Wisconsin USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7933-2280","authenticated-orcid":false,"given":"Nancy B.","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology Vanderbilt University Medical Center Nashville Tennessee USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8775-503X","authenticated-orcid":false,"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Cleveland Clinic Taussig Cancer Institute Cleveland Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-3394","authenticated-orcid":false,"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine University of Washington Seattle Washington USA"},{"name":"Clinical Research Division Fred Hutchinson Cancer Center Seattle Washington USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2328-3421","authenticated-orcid":false,"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[{"name":"Genitourinary Oncology Program Dana\u2010Farber Cancer Institute\u2010IMIM Research Lab Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1915-4491","authenticated-orcid":false,"given":"Matthew T.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1898-3522","authenticated-orcid":false,"given":"Ajjai S.","family":"Alva","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology University of Michigan Rogel Comprehensive Cancer Center Ann Arbor Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-8668","authenticated-orcid":false,"given":"Vadim S.","family":"Koshkin","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, University of California San Francisco Helen Diller Family Comprehensive Cancer Center San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"e_1_2_12_3_1","unstructured":"United States Food and Drug Administration \u201cFDA Approves Erdafitinib for Locally Advanced or Metastatic Urothelial Carcinoma \u201dJanuary 19 2024 accessed February 14 2024 https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010erdafitinib\u2010locally\u2010advanced\u2010or\u2010metastatic\u2010urothelial\u2010carcinoma."},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323"},{"key":"e_1_2_12_5_1","unstructured":"United States Food and Drug Administration \u201cFDA Grants Regular Approval to Enfortumab Vedotin\u2010ejfv for Locally Advanced or Metastatic Urothelial Cancer \u201dJuly 12 2021 accessed November 24 2023 https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010grants\u2010regular\u2010approval\u2010enfortumab\u2010vedotin\u2010ejfv\u2010locally\u2010advanced\u2010or\u2010metastatic\u2010urothelial\u2010cancer."},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035807"},{"key":"e_1_2_12_7_1","unstructured":"United States Food and Drug Administration \u201cFDA Grants Accelerated Approval to Sacituzumab Govitecan for Advanced Urothelial Cancer \u201dApril 13 2021 accessed December 20 2023 https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010grants\u2010accelerated\u2010approval\u2010sacituzumab\u2010govitecan\u2010advanced\u2010urothelial\u2010cancer."},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03489"},{"key":"e_1_2_12_9_1","unstructured":"United States Food and Drug Administration \u201cFDA Approves Enfortumab Vedotin\u2010ejfv with Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer \u201dDecember 15 2023 accessed December 17 2023 https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010enfortumab\u2010vedotin\u2010ejfv\u2010pembrolizumab\u2010locally\u2010advanced\u2010or\u2010metastatic\u2010urothelial\u2010cancer."},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117"},{"key":"e_1_2_12_11_1","unstructured":"United States Food and Drug Administration \u201cFDA Approves Nivolumab in Combination with Cisplatin and Gemcitabine for Unresectable or Metastatic Urothelial Carcinoma \u201dMarch 7 2024 accessed March 9 2024 https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010approves\u2010nivolumab\u2010combination\u2010cisplatin\u2010and\u2010gemcitabine\u2010unresectable\u2010or\u2010metastatic\u2010urothelial."},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309863"},{"key":"e_1_2_12_13_1","unstructured":"United States Food and Drug Administration \u201cPADCEV (Enfortumab Vedotin\u2010ejfv) for Injection for Intravenous Use \u201daccessed December 12 2023 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761137s007lbl.pdf."},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392\u2010022\u201000947\u20107"},{"key":"e_1_2_12_15_1","unstructured":"United States Food and Drug Administration \u201cFDA Grants Accelerated Approval to Enfortumab Vedotin\u2010ejfv for Metastatic Urothelial Cancer \u201dDecember 20 2019 accessed November 24 2023 https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010grants\u2010accelerated\u2010approval\u2010enfortumab\u2010vedotin\u2010ejfv\u2010metastatic\u2010urothelial\u2010cancer."},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01140"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.016"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01983"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2051"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1161089"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.4503"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2023.01.002"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.10.017"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34057"},{"key":"e_1_2_12_25_1","unstructured":"U.S. Department of Health and Human Services \u201cCommon Terminology Criteria for Adverse Events (CTCAE) Version 5.0 \u201dNovember 27 2017 accessed December 11 2023 https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50."},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003459"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(21)00094\u20102"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571\u2010023\u201000783\u2010w"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030713"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107778"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12335"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912\u2010022\u201001266\u20104"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538\u20107445.AM2020\u20105581"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520\u2010023\u201007793\u20105"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29918"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac001"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2021.05.020"},{"key":"e_1_2_12_39_1","unstructured":"United States Food and Drug Administration \u201cADCETRIS (Brentuximab Vedotin) for Injection for Intravenous Use \u201daccessed February 13 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125388s100lbl.pdf."},{"key":"e_1_2_12_40_1","unstructured":"United States Food and Drug Administration \u201cPOLIVY (Polatuzumab Vedotin\u2010piiq) for Injection for Intravenous Use \u201daccessed February 13 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761121s000lbl.pdf."},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.621591"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.3450"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.12.009"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_319899"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.1043"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2057"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T13:11:48Z","timestamp":1765285908000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":45,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/cam4.71284"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71284","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2024-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71284"}}